Robert Balfour is an experienced leader in the biotechnology sector, currently serving as Director at Axovia Therapeutics, where emphasis is placed on developing innovative AAV gene therapies for ciliopathies. In addition, Robert holds dual roles as Director and Founding CEO at Promatix Biosciences Ltd, focusing on cancer therapeutic innovations. Robert also contributes as a Board Observer for Oxford BioTherapeutics and Epsilogen Ltd, and serves as Investment Director at ALSA Ventures, a biotechnology investment firm. Previously, Robert held the position of Chief Business Officer at Viatem and co-founded Waimangu Ventures. Robert’s academic background includes a PhD in Neurophysiology from Imperial College London and a BSc in Physiology from the University of Southampton.
This person is not in the org chart
This person is not in any teams
This person is not in any offices